The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis.
<h4>Background</h4>Most patients with relapsing-remitting multiple sclerosis (RRMS) eventually enter a secondary progressive (SPMS) phase, characterized by increasing neurological disability. The mechanisms underlying transition to SPMS are unknown and effective treatments and biomarkers...
Guardado en:
Autores principales: | Ellen Iacobaeus, Petra Amoudruz, Mikael Ström, Mohsen Khademi, Lou Brundin, Jan Hillert, Ingrid Kockum, Vivianne Malmström, Tomas Olsson, Emma Tham, Fredrik Piehl |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c982ac1812ba4ab7accd75bf88edbf25 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.
por: Mohsen Khademi, et al.
Publicado: (2013) -
Smoking and Epstein–Barr virus infection in multiple sclerosis development
por: Anna Karin Hedström, et al.
Publicado: (2020) -
Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis.
por: Jenny Link, et al.
Publicado: (2012) -
Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
por: Karl E. Carlström, et al.
Publicado: (2019) -
Blocking PDGF-CC signaling ameliorates multiple sclerosis-like neuroinflammation by inhibiting disruption of the blood–brain barrier
por: Manuel Zeitelhofer, et al.
Publicado: (2020)